论文部分内容阅读
目的:通过光学相干断层显像(OCT)分析强化他汀治疗对支架内膜增生的的影响。方法:入选2014-01-2016-02在我院心内科行冠脉造影+经皮冠状动脉支架植入术(PCI)治疗并予术后1年后行OCT复查的患者44例分为2组:强化剂量他汀治疗组(强化组,阿托伐他汀40mg/d或瑞舒伐他汀20mg/d),常规剂量他汀治疗组(常规组,阿托伐他汀20mg/d、10mg/d或瑞舒伐他汀10mg/d、5mg/d);比较2组之间的临床基线水平、PCI术中参数及复查OCT指标的差异;结果:2组患者的临床基线资料、PCI术中各项参数指标类似,OCT结果发现强化组支架内膜增生厚度较常规组更薄[(212.86±85.16)μm∶(355.65±155.62)μm,P<0.05],同质性比例更高(81.0%∶47.8%,P<0.05)。结论:强化他汀治疗能够抑制支架内膜增生,且发生同质性比例相对更高,可能对稳定内膜及降低支架内再狭窄更具有优势。
OBJECTIVE: To analyze the effect of statin therapy on stent intima hyperplasia by optical coherence tomography (OCT). Methods: Forty-four patients who underwent OCT in our hospital from January 2014 to June 2016 underwent coronary angiography + percutaneous coronary stent implantation (PCI) and 1 year after operation were divided into 2 groups (Intensive group, atorvastatin 40mg / d or rosuvastatin 20mg / d), normal dose statin treatment group (conventional group, atorvastatin 20mg / d, 10mg / d or Ruishu The difference between the baseline parameters of PCI and the index of OCT after PCI was compared between two groups. Results: The baseline data of two groups of patients with similar parameters of PCI The OCT results showed that the thickness of intimal hyperplasia in the stenting group was thinner than that in the conventional group [(212.86 ± 85.16) μm: (355.65 ± 155.62) μm, P <0.05], and the homogeneity was higher (81.0% vs 47.8%, P <0.05). CONCLUSIONS: Fortified statin treatment can inhibit stent intimal hyperplasia with a relatively high proportion of homogeneity, which may be more advantageous for stabilizing the endometrium and reducing in-stent restenosis.